International Clinical Trial: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856004) titled 'A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment' on Sept. 29.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: BeOne Medicines

Condition: Hepatic Impairment Healthy Adult Participants

Intervention: Drug: Tacabrutideg

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 22, 2026

Target Sample Size: 24

To know more, visit https://clinicaltrial...